Ak. Gurbuz et al., COLORECTAL NEOPLASIA IN PATIENTS WITH ULCERATIVE-COLITIS AND PRIMARY SCLEROSING CHOLANGITIS, Diseases of the colon & rectum, 38(1), 1995, pp. 37-41
PURPOSE: Most patients with primary sclerosing cholangitis also have u
lcerative colitis. It has been suggested that in the presence of prima
ry sclerosing cholangitis the risk of colorectal dysplasia and carcino
ma is greater than in patients with ulcerative colitis alone. METHODS:
In a retrospective study, we evaluated the possibility of colorectal
cancer or dysplasia in 35 consecutive patients with primary sclerosing
cholangitis and ulcerative colitis seen at The Johns Hopkins Hospital
between 1979 and 1991. RESULTS: Thirteen of the 35 patients (37 perce
nt) with ulcerative colitis and primary sclerosing cholangitis had col
orectal neoplasia (5 with adenocarcinoma and 8 with dysplasia). In the
27 patients undergoing colonoscopic biopsy surveillance, the cumulati
ve incidence at 28 years of colorectal cancer was 18.5 percent and for
colorectal dysplasia it was 29.6 percent. The high incidence of color
ectal cancer was less than the rate of colorectal cancer in patients w
ith extensive colitis of childhood onset without primary sclerosing ch
olangitis (35 percent), but the rate of colorectal cancer and dysplasi
a (48.1 percent) is similar to the highest rates of cancer noted in th
e comparison group. Because patients had subtle, quiescent colitis, a
short time from diagnosis of ulcerative colitis to diagnosis of colore
ctal neoplasia was noted (mean, 12.2 +/- 9 years; less than 8 years in
5/13 (38.5 percent) patients). CONCLUSION: Ulcerative colitis patient
s with primary sclerosing cholangitis appear to have a high frequency
of colorectal cancer but a rate lower than expected in patients with e
xtensive quiescent ulcerative colitis of childhood onset alone. Howeve
r, exact conclusions are complicated by the high incidence of colorect
al dysplasia found, which portends malignant transformation. Because o
f the subtle nature of colitis, the diagnosis of ulcerative colitis is
often delayed, and surveillance programs should start as soon as ulce
rative colitis is diagnosed.